Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03522129
Recruitment Status : Recruiting
First Posted : May 11, 2018
Last Update Posted : June 6, 2018
Information provided by (Responsible Party):
Cognition Therapeutics

Brief Summary:
This is a multi‐center, Phase 1b, randomized, double‐blind, placebo‐controlled parallel‐group trial in adults with mild to moderate AD.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: CT1812 Drug: Placebo Phase 1

Detailed Description:
This is a multi‐center, Phase 1b, randomized, double‐blind, placebo‐controlled parallel‐group trial in adults with mild to moderate AD. The primary endpoint is the change from the baseline CSF Amyloid beta oligomer concentration after dosing with CT1812 versus placebo. The change from baseline will be measured through a number of exploratory endpoints as indicated below. For each subject, the baseline CSF oligomer concentration will be computed as the average of the measurements from hours -4, -3, -2 and -1 and 0.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Phase 1b, randomized, double‐blind, placebo‐controlled parallel‐group trial in adults with mild to moderate AD.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double-blind for study site and participants
Primary Purpose: Treatment
Official Title: A Pilot Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease
Actual Study Start Date : May 16, 2018
Estimated Primary Completion Date : September 30, 2019
Estimated Study Completion Date : December 31, 2019

Arm Intervention/treatment
Active Comparator: Active Treatment- CT1812 560 mg Drug: CT1812
Active Study Drug
Other Name: Study Drug

Active Comparator: Active Treatment- CT1812 280 mg Drug: CT1812
Active Study Drug
Other Name: Study Drug

Active Comparator: Active Treatment- CT1812 90 mg Drug: CT1812
Active Study Drug
Other Name: Study Drug

Placebo Comparator: Placebo Comparator - Placebo Drug: Placebo
Non-active study drug
Other Name: Matching Placebo

Primary Outcome Measures :
  1. Measuring the displacement of Amyloid beta oligomers into cerebrospinal fluid (CSF) [ Time Frame: 48 hours ]
    evidence of oligomer displacement as demonstrated by a clear rise in CSF oligomer concentration relative to baseline and placebo

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Subjects may be included in the study only if they meet all of the following criteria:

  • Men, and women of non-childbearing potential, 50-85 years of age inclusively, with a diagnosis of mild to moderate Probable Alzheimer's Disease Dementia according to the 2011 NIA-AA criteria and at least a 6 month decline in cognitive function documented in the medical record.
  • Neuroimaging (MRI) obtained during screening consistent with the clinical diagnosis of Alzheimer's disease and without findings of significant exclusionary abnormalities (see exclusion criteria, number 3).
  • MMSE 16-26 inclusive. Subjects must, in the opinion of the investigator, be able to comply with study procedures and must understand the consent process. The investigator will use his or her clinical judgment in conjunction with the cognitive screening assessments to determine whether the subject meets these criteria in a manner that is consistent with local clinical practice and standards. Subjects with borderline low MMSE at screening may undergo repeat MMSE administration if extenuating circumstances were present at original assessment.
  • A positive amyloid scan (florbetaben F18, florbetapir F18, or flutametamol F18) at screening or within prior 12 months, as read by the certified, site-designated PET scan reader.
  • Must consent to apolipoprotein E (ApoE) genotyping
  • Subjects must have a caregiver or study partner who can participate in all clinic visits.
  • Patients living at home or in the community (assisted living acceptable)
  • Able to swallow CT1812 capsules.
  • Stable pharmacological treatment of any other chronic conditions for at least 30 days prior to screening.
  • Subjects must be capable of providing written informed consent to the study procedures and for use of protected health information [Health Insurance Portability and Accountability Act (HIPAA) Authorization, if applicable]. Written informed consent also shall be obtained from the responsible caregiver or study partner. All consent processes must be undertaken in the presence of a witness and prior to any study procedures.
  • Subjects shall be generally healthy with mobility (ambulatory or ambulatory-aided, i.e., walker or cane), vision and hearing (hearing aid permissible) sufficient for compliance with testing procedures.
  • Must be able to complete all screening evaluations.

Exclusion Criteria:

  • Hospitalization or change of chronic concomitant medication within one month prior to screening.
  • Patients living in a continuous care nursing facility
  • Screening MRI of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage or infarct >1 cm3, >3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g. abscess or brain tumor such as meningioma). If a small incidental meningioma is observed, the medical monitor may be contacted to discuss eligibility.
  • Clinical or laboratory findings consistent with:

    • Other primary degenerative dementia, (dementia with Lewy bodies, fronto-temporal dementia, Huntington's disease, Jacob-Creutzfeld Disease, Down's syndrome, etc.);
    • Other neurodegenerative condition (Parkinson's disease, amyotrophic lateral sclerosis, etc.);
    • Seizure disorder; or
    • Other infectious, metabolic or systemic diseases affecting the central nervous system (syphilis, present hypothyroidism.) Present vitamin B12 or folate deficiency or other laboratory abnormalities of possible clinical significance should be discussed with medical monitor to determine eligibility.
  • A current DSM-V diagnosis that would interfere with the subject's ability to participate in the study. Patients with depressive symptoms successfully managed by a stable dose of an antidepressant are allowed entry.
  • Any prior history of suicidal thoughts or behavior that are believed by the investigator to represent a current safety risk.
  • Clinically significant, advanced or unstable disease that may interfere with outcome evaluations, such as:

    • Chronic liver disease, liver function test abnormalities or other signs of hepatic insufficiency (ALT, AST, > 1.5 ULN);
    • Respiratory insufficiency;
    • Renal insufficiency, defined as eGFR <40 mL/min based on the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula,,using,ckd,epi;
    • Heart disease (myocardial infarction, unstable angina, heart failure, cardiomyopathy within six months before screening). If a subject has a history of heart disease of questionable clinical significance, the medical monitor may be contacted to discuss eligibility.
    • Bradycardia (<50 beats/min.) or tachycardia (>100 beats/min.). Otherwise healthy subjects with borderline bradycardia may be discussed with the medical monitor to determine eligibility.
    • Poorly managed hypertension (systolic >160 mm Hg and/or diastolic >95 mm Hg) or hypotension (systolic <90 mm Hg and/or diastolic <60 mm Hg); or
    • Uncontrolled diabetes defined by HbA1c >7.5
  • History of cancer within 3 years of screening with the exception of fully excised non- melanoma skin cancers or non-metastatic prostate cancer that has been stable for at least 6 months.
  • History of acute/chronic hepatitis B or C and/or carriers of hepatitis B (seropositive for Hepatitis B surface antigen [HbsAg] or anti-Hepatitis C [HCV] antibody).
  • Clinically significant abnormalities in screening laboratory tests, including:

    • hematocrit less than 35% for males and less than 32% for females,
    • platelet cell count of < 120,000/uL, or
    • INR >1.4 or other coagulopathy, confirmed by repeat analysis
    • lymphocyte count less than 1200/ul
  • Disability that may prevent the patient from completing all study requirements (e.g. blindness, deafness, severe language difficulty, etc.)
  • Women who are fertile and of childbearing potential.
  • Within 4 weeks of screening visit or during the course of the study, concurrent treatment with antipsychotic agents, antiepileptics, centrally active anti-hypertensive drugs (e.g., clonidine, l-methyl dopa, guanidine, guanfacine, etc.), sedatives, opioids, mood stabilizers (e.g., valproate, lithium); or benzodiazepines, with the following exceptions:

    • benzodiazepines must not be administered within 5 half-lives of cognitive testing;
    • administration of selective serotonin re-uptake inhibitors (SSRI) may be continued if doses have been stable for 60 days prior to Screening;
    • low dose lorazepam may be used for sedation prior to MRI scan for those patients requiring sedation. At the discretion of the investigator, 0.5 to 1 mg may be given orally prior to scan with a single repeat dose given if the first dose is ineffective. No more than a total of 2 mg lorazepam may be used for the MRI scan.
    • Any disorder that could interfere with the absorption, distribution, metabolism or excretion of drugs (e.g. small bowel disease, Crohn's disease, celiac disease, or liver disease.)
  • Nootropic drugs except for AD meds (acetylcholinesterase inhibitors and memantine) stable for at least 30 days
  • Suspected or known drug or alcohol abuse, i.e. more than approximately 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine) per day indicated by elevated MCV significantly above normal value at screening.
  • Suspected or known allergy to any components of the study treatments.
  • Enrollment in another investigational study or intake of investigational drug within the previous 30 days or five half lives of the investigational drug, whichever is longer.
  • Intake of drugs or substances potentially involved in clinically significant CYP3A4 or P-gp mediated drug interactions with CT1812, within 4 weeks or five half-lives of the interacting drug prior to administration of CT1812 and throughout the course of the study. Grapefruit juice should be avoided in the two weeks prior to dosing. See Appendix A for a complete list of prohibited substances.
  • Previous exposure to anti Aβ vaccines
  • Exposure to passive immunotherapies for AD (e.g. monoclonal antibodies), or BACE inhibitors within the previous 180 days.
  • Contraindication to undergoing an LP including, but not limited to: inability to tolerate an appropriately flexed position for the time necessary to perform an LP; international normalized ratio (INR) > 1.4 or other coagulopathy; platelet count of < 120,000/μL; infection at the desired lumbar puncture site; taking anti-coagulant medication within 90 days of screening (Note: low dose aspirin is permitted); degenerative arthritis of the lumbar spine; suspected non-communicating hydrocephalus or intracranial mass; prior history of spinal mass or trauma.
  • Any condition, which in the opinion of the investigator or the sponsor makes the patient unsuitable for inclusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03522129

Contact: Alyssa Galley 617-459-9134

United States, Pennsylvania
University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Beth Harders    215-573-0085   
Sponsors and Collaborators
Cognition Therapeutics
Study Director: Alyssa Galley Cognition Therapeutics, Inc.
Principal Investigator: Yvette Sheline, MD University of Pennsylvania

Responsible Party: Cognition Therapeutics Identifier: NCT03522129     History of Changes
Other Study ID Numbers: COG0104
First Posted: May 11, 2018    Key Record Dates
Last Update Posted: June 6, 2018
Last Verified: June 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Cognition Therapeutics:
Alzheimer's Disease

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders